Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Zillow Group Inc Class A — how do they compare? Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B), while Zillow Group Inc Class A trades at $29.87 (market cap $6.59B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 19.4× Zillow Group Inc Class A's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Zillow Group Inc Class A for 86 Days on average.
| VRTX | ZG | |
|---|---|---|
Market Cap | $127.55B | $6.59B |
Volume | 1,487,944 | 1,361,381 |
Sector | Health | Media |
52-Week High | $557.96 | $74.58 |
52-Week Low | $407.37 | $27.70 |
Typical Hold Time | 120 Days | 86 Days |
Enterprise Value | $121.68B | $6.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, with a bearish technical signal despite strong fundamentals. The company maintains dominant cystic fibrosis market position with 86% gross margins and 35% net income margin. Recent positive Phase 2b data for inaxaplin in kidney disease shows pipeline expansion potential. Revenue grew to $12.0B in 2025 with $3.95B net income, recovering from 2024's loss.
Analyst consensus remains strongly bullish with 84% buy ratings and $573.50 price target, representing 14% upside. Key risks include pipeline execution and competitive pressures. The stock offers growth potential through gene therapy expansion but faces volatility from clinical trial outcomes and market sentiment shifts.
Zillow Group (ZG) trades at $29.9, up 6.9% over 24 hours, with a mixed technical outlook showing bullish oscillators but bearish moving averages. Fundamentally, the company reported a net income of $23 million in 2025, marking a return to profitability after losses in prior years, supported by revenue growth to $2.58 billion. Analyst sentiment is divided, with a consensus price target of $48.87, though recent news highlights competitive pressures and housing market headwinds.
The stock presents a turnaround opportunity as profitability improves, but risks include sensitivity to interest rates and real estate cycles. With nearly half of analysts rating it a buy, upside exists if execution continues, yet volatility from macroeconomic factors warrants caution for investors seeking stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
